Ethinyl Estradiol/Norethindrone
Phase 2Small molecule
AstraZenecaEthinyl Estradiol/Norethindrone is one of 5 small molecule programs targeting Hyperandrogenism. It is currently in Phase 2.
1
Indications
3
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Hyperandrogenism
#DrugCompanyPhaseTrials
1Lupron
AbbViePhase 2
Aldactone
PfizerPhase 1
Micronized Progesterone
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 1
Ethinyl Estradiol/Norethindrone
AstraZenecaPhase 2
Rhcg
UUniversity of Virginia
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company